vertex cystic fibrosi portfolio creat narrow moat
updat forecast estim may
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jul
estim may
price data jul
rate updat jul
currenc amount express
valuat growth profit
methodolog valu compani
vertex pharmaceut best known
discov incivek blockbust hepat viru drug futur
tie robust cystic fibrosi portfolio approv
treatment kalydeco orkambi well addit pipelin
asset expect creat domin franchis lucr
abl
kalydeco success launch vertex well
posit cf genet disord affect approxim
peopl world-wide character progress deadli declin
lung function number target patient small
command six-figur price
disease-modifi drug seriou orphan indic drug
launch price close treatment
less cf suffer certain genet mutat
name gate mutat despit aggress price
major patient popul alreadi captur
vertex pipelin strategi develop drug known
corrector work combin kalydeco order treat
genet subtyp make larger portion cf patient
orkambi combo regimen approv
treat peopl common cf mutat
homozyg repres half cf popul
anticip vertex reach billion-plu peak sale
patient segment alon especi approv
next-gener combo symdeko year impress
result triplet combin pave way vertex
next-biggest opportun difficult-to-treat het/min cf patient
segment less third total cf popul
pois
dramat chang treatment cf earn firm
domin posit market world-wide chronic natur
therapi limit competit horizon heighten
market attract given posit market dynam
think vertex cf program could grow billion within
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
discov develop small-molecul drug
treatment seriou diseas key drug kalydeco orkambi
symdeko cystic fibrosi addit sever mid- late-stag
product target market vertex success develop
commerci two hiv proteas inhibitor outlicens
glaxosmithklin vertex pipelin also includ therapi treatment
cancer pain inflammatori diseas influenza rare diseas
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
valuat growth profit jul
maintain fair valu estim firm
per share valuat rest firm cystic
fibrosi program pipelin continu ramp-up
orkambi acceler
launch
next-gener symdeko tezacaftor kalydeco
biggest driver model homozyg
popul repres roughli cf patient
assum lower net price discount
 outsid larger
patient popul repres opportun
billion peak sale assum patient deter
orkambi risk/benefit profil captur
effect safer symdeko
second-largest
heterozyg popul cystic fibrosi patient
attribut probabl success tripl
combin regimen kalydeco two corrector
molecul full market launch model
probability-adjust peak sale billion
kalydeco monotherapi larg satur cf
popul gate mutat
howev late-stag competit sight
believ small opportun label expans
margin price increas gener peak sale close
billion vertex prove success expand
drug label genet subtyp includ nearli
potenti cystic fibrosi patient
origin approv price assumpt kalydeco
roughli per year
rest word versu current list price
cancer influenza pain
spinal cord injuri -- probabl approv less
base earlier stage develop overal
think vertex top line averag compound annual
growth next five year driven primarili
blockbust sale cf franchis think rise
product sale propel firm profit
ultim drive oper margin
return invest capit
bull case consid impact increas
annual price orkambi upcom triplet regimen
rais probabl triplet approv
heterozyg patient group increas
probabl approv rest vertex non-cf
pipelin case fair valu estim increas
per share return invest capit grow
bear case assum compani combin
therapi difficult-to-treat heterozyg
patient stumbl price pressur caus firm
cut price orkambi futur therapi
case think compani valu would fall per
share return invest capit pressur
believ vertex current relianc limit rang
market product center one therapeut area
warrant medium uncertainti rate given pipelin
vertex portfolio disease-modifi drug form
basi narrow econom moat rate compani
well support lengthi patent protect first-mov
statu cystic fibrosi market kalydeco launch
orkambi combin
next-gener symdeko
reach market year
disease-modifi drug market kalydeco
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
regimen use next-gener corrector pivot
test would expos vertex next-largest opportun
cf -- het/min patient compos nearli
cf genet disord affect roughli peopl
world-wide caus progress deadli declin
lung function number patient small
six-figur price vertex disease-modifi drug
make megablockbust market potenti addit
experienc welcom
commerci regulatori environ due lack
treatment sever afflict chronic natur
therapi limit competit near-term horizon
heighten market attract patent
kalydeco orkambi extend
respect european union
ward gener competit galapago partnership
remain closest pipelin threat vertex
cf franchis still year away reach
market give vertex time entrench current
market therapi cf prescrib popul also
potenti launch second-gener product
element lead us award compani narrow moat
rate
transform
execut
assign vertex posit moat trend rate base
promis clinic result pipelin product lack
near-term competit cystic fibrosi allow
domin attract market compani
demonstr abil intern develop success
market drug kalydeco orkambi boost
confid drug candid recent termin
novarti phase potenti drug mean galapago
partner remain major medium-term
threat howev phase candid face sever
year clinic trial need demonstr clearli
orkambi symdeko make backbon cf
therapi believ vertex remain leader
rare-diseas space forese futur
given limit treatment option cystic fibrosi
chronic natur diseas vertex abl command
strong price power cours patient life
kalydeco cost close treatment less
cf suffer certain genet mutat
despit aggress price uptak swift
almost elig patient therapi vertex
strategi develop drug known corrector
work combin kalydeco order treat
genet subtyp make larger portion cf
patient orkambi symdeko treat peopl
common cf mutat homozyg drug
price per year current target roughli
cf popul pediatr label expans
increas target popul approxim
patient firm cf pipelin drug includ
second-gener corrector use
combin kalydeco potent treatment
difficult-to-treat cf subtyp approv triple-combin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
superior efficaci and/or safeti profil kalydeco
orkambi symdeko order impact vertex
commerci momentum also phase
cystic fibrosi drug ataluren note therapi
target small percentag cf popul
nonsens mutat overlap
beyond cf vertex remain pipelin candid
rel uncertain opportun compani
number pipelin drug target cancer partnership
merck pain spinal cord injuri influenza
partnership johnson johnson earli
say whether prospect becom signific
revenu driver believ vertex ampl potenti
diversifi cf portfolio would bolster moat
advantag firm exit hepat market
due incivek precipit declin limit non-cf
pipelin vertex depend cf franchis key
risk posit moat trend opportun
develop anticip howev firm
aggress invest early-stag pipelin beyond cf
enough cash target tuck-on acquisit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oth firm cf program pois domin
lucr market forese futur base
disease-modifi potenti drug chronic
use patient limit competit
overtex record success launch drug
differenti emerg biotech
often falter commerci
lead drug candid mostli
discov in-hous lend credibl drug-
discoveri technolog potenti gener
overtex valuat rest cf pipelin
compani could fail diversifi beyond cf
oth sky-high price orphan drug like kalydeco
unsustain particularli price-consci european
vertex nich cystic fibrosi market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
year-end vertex nearli billion cash
million debtlik leas oblig like
biotechnolog compani vertex histor oper
loss high cost clinic trial
research loss financ larg
offer equiti debt secur collabor
fund arrang develop mileston
royalti partner howev success
launch orkambi kalydeco compani
abl gener signific revenu allow
build signific cash cushion suffici fund
develop commerci remain
development-stag candid even orkambi launch
still ramp expect vertex reach
sustain profit gener signific
cash flow thereaft expect vertex use
cash build diversifi rare-diseas portfolio
look beyond cystic fibrosi market
compani futur reli emerg cf franchis
signific amount vertex fair valu hing
commerci success orkambi larg
homozyg patient popul although expect
drug larg captur patient popul
disease-modifi drug market increas
patient discontinu orkambi due bronchospasm
side effect would curtail posit view firm
growth prospect moat trend addit
increas competit cf develop pipelin
could threaten vertex current leadership posit
progress vertex next-gener doublet candid
display bronchospasm effect
help mitig risk assumpt high price
underpin view blockbust potenti cf
market
payer
particularli austerity-strap govern europ may
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
efficaci
balk high price even drug treat orphan
indic nation institut
excel initi deni reimburs
cost-effect concern hand
kalydeco current price maintain
futur combin therapi much larger
number patient estim may prove
conserv firm risk compound
early-stag natur remain pipelin includ
experiment treatment influenza pain cancer
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
rate jeffrey leiden becam ceo chairman
serv board two year previous
work presid
manag director life scienc ventur capit
firm believ experi particularli stint
pharma asset compani launch
new drug priorit pipelin inde incivek
launch quit success
particularli consid commerci issu
commonli affect emerg biotech firm
howev think investor would better serv
compani separ ceo chairman role
addit think manag compens
histor high although recent measur spur
sharehold vote curtail amount go forward
leiden total compens million
sever senior manag compens packag
million respons sharehold disapprov
previous excess amount compani also
probe secur exchang commiss
seri larg insid stock sale posit clinic news
past year cfo sold vest
hold compani stock surg
promis result cf trial sale
appropri took place prearrang stock-sel
plan question manag long-term prioriti
incent insid abl will sell materi
amount stock rather maintain sharehold
long-term investor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
moat posit trend rate vertex jun
reiter per share fair valu estim
vertex cystic fibrosi competitor galapago
partner announc subpar phase result one
tripl combin regimen note
fibrosi collabor
galapago cast shadow rest galapago
program believ market previous fail
appreci narrow moat advantag vertex cystic
fibrosi franchis correct today news
place stock closer fair valu estim
cystic
galapago phase pelican studi addit
corrector molecul vertex doublet regimen
orkambi lumacaftor/ivacaftor met primari endpoint
cf patient homozyg mutat
largest cf patient segment fail show greater
efficaci vertex tripl combin regimen abbvi
decid move forward
reiter prior note
vertex set high bar competit multipl drug
candid late stage develop compani
current evalu two triplet regimen pivot test
featur potenti drug ivacaftor current market
kalydeco cf patient gate mutat
kalydeco homozyg cf patient symdeko
either new corrector model
anticip launch either vertex tripl drug
regimen difficult-to-treat heterozyg minimal-
function segment next largest opportun
firm patient volum firm would also need
pay royalti cystic fibrosi foundat
new corrector would boost
still way believ firm face
uphil battl vertex incumb statu cf
market drug remark efficaci unimpress
profil undermin rest galapago
prospect vertex significantli weaken
largest near-term threat vertex cf franchis asid
galapagos/abbvi competitor develop
therapeut gain traction phase test
mile behind vertex gene therapi medium-term
threat vertex firm alreadi foothold
space partnership rna therapi
econom advantag grow pipelin competit
momentum set vertex solid year share
vertex momentum first quarter strongli posit
firm meet full-year expect
increas fair valu estim firm per
share reflect time valu money
margin optimist sale expect kalydeco
believ vertex share still leeway upsid
market may underestim vertex pipelin portfolio
beyond cystic fibrosi view
modest probability-weight sale contribut
compani non-cf pipelin asset given early-stag
natur believ vertex defens cystic fibrosi
powerhous give firm high margin development
misstep form basi narrow econom moat
approv launch symdeko next-gener
orkambi cystic fibrosi patient two copi
mutat coupl steadi growth
kalydeco drove top-lin sale quarter kalydeco
monotherapi larg satur cystic fibrosi
popul gate mutat although growth appear
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
ever-so-slightli robust previou
forecast expect symdeko higher efficaci
fewer safeti issu orkambi expand
homozyg cf popul vertex drug name
captur patient discontinu orkambi never
start treatment uptak symdeko
anticip cannib orkambi sale expect
continu reimburs agreement european market
approv pediatr patient partial off-set
declin near term symdeko approv europ
anticip second half year would
acceler drug launch
next-largest commerci driver vertex approv
cf patient minim cftr protein function mutat
well way compani move forward pivot
test two tripl combin regimen one program
featur corrector
patient enrol on-going model anticip
launch addit next-gener corrector
also develop development progress
once-daili potenti deuter version
kalydeco twice-daili drug believ vertex cystic
pipelin
competitor food drug administr
request dose-rang data
candid progress pivot test push
timelin launch once-daili drug howev
updat time affect valuat
believ success would rais barrier entri
competitor would contribut increment sale
well-defend
introduct gene therapi remain medium-
term threat vertex partnership rna
therapi crispr gene therapi high
bar set vertex drug segment cystic
fibrosi popul reason mitig risk
view movement vertex non-cf portfolio first
quarter -- includ posit proof-of-concept data
acut pain permiss advanc gene therapi drug
clinic studi b-thalassemia crispr
therapeut -- also contribut posit moat trend
rate vertex given compani ampl cash hand
manag team strong experi cystic
fibrosi confid vertex abil pivot
share fairli valu sentiment heat feb
vertex cystic fibrosi powerhous finish year
solid growth augment slightli fourth-
million larg fell line expect
anticip major chang per share fair valu
estim view share appear fairli valu
gradual build investor enthusiasm past
month two anticip catalyst first
progress two combo drug regimen pivot trial
announc conjunct fourth-quart result
second expect approv vertex next-gener
orkambi tezacaftor kalydeco cf patient two
copi mutat materi
end februari fda pdufa date feb vertex
lockstep execut cf develop program
entrench moat creat solid foundat
build post-cf drug portfolio
kalydeco monotherapi continu benefit strong
patient uptak grow year year quarter
drug larg satur applic cf patient
market lower growth expect futur
orkambi address larger cf patient popul
two copi mutat gener
growth year year look forward assum
success regulatori approv launch tezacaftor/
kalydeco key driver better penetr rate
patient popul minim inventori stock
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fourth quarter may weigh first-quart sale growth
model acceler growth overal thank
anticip launch tezacaftor/kalydeco
continu uptak kalydeco orkambi pediatr
popul compani transit well past
prerevenu day expect greater oper leverag
support bottom line despit increas research
develop spend support pivot trial
alreadi high expect vertex tripl
combin drug regimen hard-to-treat cf patient
popul one mutat one
mutat result minim cftr protein function
vertex comprehens clinic trial strategi derisk
program corrector drug four option
plan advanc phase studi
thank
combin tezacaftor/kalydeco appear
efficaci combo preliminari basi
slate begin first half year meanwhil
compani expect progress anoth set pivot
studi combin tezacaftor deuter
kalydeco once-daili drug regimen --
durat trial still air howev
base past commentari model market entri
triple-combo drug regimen two superb molecul
hand think compani well-posit captur
next largest set cf patient
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
